Last reviewed · How we verify
Ezogabine/Retigabine IR
Ezogabine/Retigabine IR is a Potassium channel opener Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Partial-onset seizures (adjunctive therapy in adults).
Ezogabine opens voltage-gated potassium channels in neurons, reducing neuronal excitability and seizure activity.
Ezogabine opens voltage-gated potassium channels in neurons, reducing neuronal excitability and seizure activity. Used for Partial-onset seizures (adjunctive therapy in adults).
At a glance
| Generic name | Ezogabine/Retigabine IR |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Potassium channel opener |
| Target | Kv7 (KCNQ) voltage-gated potassium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Ezogabine is a potassium channel opener that stabilizes the open state of voltage-gated potassium channels (particularly Kv7 channels), allowing potassium efflux and hyperpolarization of neuronal membranes. This reduces neuronal firing and propagation of seizure activity. It is the first-in-class Kv7 channel opener approved for epilepsy.
Approved indications
- Partial-onset seizures (adjunctive therapy in adults)
Common side effects
- Dizziness
- Somnolence
- Confusion
- Vertigo
- Tremor
- Blurred vision
- Urinary retention
- QT prolongation
Key clinical trials
- Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures (PHASE4)
- Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (PHASE3)
- A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (PHASE3)
- Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (PHASE3)
- An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation. (PHASE1)
- Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ezogabine/Retigabine IR CI brief — competitive landscape report
- Ezogabine/Retigabine IR updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Ezogabine/Retigabine IR
What is Ezogabine/Retigabine IR?
How does Ezogabine/Retigabine IR work?
What is Ezogabine/Retigabine IR used for?
Who makes Ezogabine/Retigabine IR?
What drug class is Ezogabine/Retigabine IR in?
What development phase is Ezogabine/Retigabine IR in?
What are the side effects of Ezogabine/Retigabine IR?
What does Ezogabine/Retigabine IR target?
Related
- Drug class: All Potassium channel opener drugs
- Target: All drugs targeting Kv7 (KCNQ) voltage-gated potassium channels
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Partial-onset seizures (adjunctive therapy in adults)
- Compare: Ezogabine/Retigabine IR vs similar drugs
- Pricing: Ezogabine/Retigabine IR cost, discount & access